$2.04 Billion is the total value of Camber Capital Management LP's 32 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HCA | HCA HEALTHCARE INC | $121,250,000 | +10.4% | 1,250,000 | 0.0% | 5.95% | +10.8% | |
| UHS | UNIVERSAL HLTH SVCS INCcl b | $92,360,000 | +4.5% | 780,000 | 0.0% | 4.54% | +4.8% | |
| GHDX | GENOMIC HEALTH INC | $76,914,000 | -8.5% | 2,458,100 | 0.0% | 3.78% | -8.2% | |
| GSK | GLAXOSMITHKLINE PLCsponsored adr | $58,605,000 | +10.1% | 1,500,000 | 0.0% | 2.88% | +10.5% | |
| AMAG | AMAG PHARMACEUTICALS INC | $53,398,000 | +52.1% | 2,650,000 | 0.0% | 2.62% | +52.5% | |
| MYGN | MYRIAD GENETICS INC | $44,325,000 | -14.0% | 1,500,000 | 0.0% | 2.18% | -13.7% | |
| BKD | BROOKDALE SENIOR LIVING | $43,615,000 | -30.8% | 6,500,000 | 0.0% | 2.14% | -30.6% | |
| DRNA | DICERNA PHARMACEUTICALS INC | $9,560,000 | +5.9% | 1,000,000 | 0.0% | 0.47% | +6.1% | |
| SGRY | SURGERY PARTNERS INC | $2,317,000 | +41.7% | 135,084 | 0.0% | 0.11% | +42.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.